View in EDS HTML Full Text PDF Full Text

Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: Antitumor effects and immune‐mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Authors: Ito, Takanori1 (AUTHOR) tahkun56@med.nagoya-u.ac.jp, Shimose, Shigeo2 (AUTHOR), Tani, Joji3 (AUTHOR), Tomonari, Tetsu4 (AUTHOR), Saeki, Issei5 (AUTHOR), Takeuchi, Yasuto6 (AUTHOR), Hatanaka, Takeshi7 (AUTHOR), Sasaki, Kyo8 (AUTHOR), Kakizaki, Satoru9 (AUTHOR), Kanayama, Yuki7 (AUTHOR), Yoshioka, Naoki10 (AUTHOR), Naito, Takehito11 (AUTHOR), Takeuchi, Mamiko12 (AUTHOR), Yasunaka, Tetsuya13 (AUTHOR), Sakata, Masahiro14 (AUTHOR), Iwamoto, Hideki2,15 (AUTHOR), Itano, Satoshi16 (AUTHOR), Shirono, Tomotake2 (AUTHOR), Tanabe, Norikazu17 (AUTHOR), Yamamoto, Takafumi1 (AUTHOR)
Source: Hepatology Research. Apr2025, Vol. 55 Issue 4, p577-587. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13866346
DOI:10.1111/hepr.14151